Analysts forecast that ICON Public Limited (NASDAQ:ICLR) will announce sales of $748.50 million for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for ICON Public’s earnings, with the highest sales estimate coming in at $763.88 million and the lowest estimate coming in at $738.75 million. ICON Public posted sales of $725.41 million during the same quarter last year, which would indicate a positive year over year growth rate of 3.2%. The business is expected to announce its next quarterly earnings results on Wednesday, February 24th.
On average, analysts expect that ICON Public will report full-year sales of $2.79 billion for the current financial year, with estimates ranging from $2.78 billion to $2.80 billion. For the next year, analysts anticipate that the firm will report sales of $3.14 billion, with estimates ranging from $3.06 billion to $3.21 billion. Zacks’ sales averages are a mean average based on a survey of analysts that cover ICON Public.
Separately, Zacks Investment Research upgraded ICON Public from a “sell” rating to a “hold” rating in a research report on Wednesday, January 13th. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. ICON Public has a consensus rating of “Hold” and a consensus target price of $185.00.
NASDAQ ICLR traded down $1.32 during trading hours on Thursday, reaching $206.93. 7,997 shares of the company’s stock were exchanged, compared to its average volume of 218,942. The stock has a market cap of $11.10 billion, a PE ratio of 34.71, a price-to-earnings-growth ratio of 2.85 and a beta of 0.91. The firm has a fifty day moving average of $208.58 and a 200-day moving average of $195.65. ICON Public has a one year low of $104.28 and a one year high of $223.62.
ICON Public Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Further Reading: What are momentum indicators and what do they show?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.